Impact of the COVID-19 Pandemic on the Diagnosis of Tuberculosis in Brazil: Is the WHO End TB Strategy at Risk?
- 1Health Science Graduate Program, Universidade Federal de Sergipe, São Cristóvão, Brazil
- 2Parasitic Biology Graduate Program, Universidade Federal de Sergipe, São Cristóvão, Brazil
- 3Tropical Medicine Graduate Program, Universidade Federal de Pernambuco, Recife, Brazil
- 4Department of Medicine, Universidade Federal de Sergipe, Aracaju, Brazil
- 5Department of Health Education, Universidade Federal de Sergipe, Lagarto, Brasil
- 6Department of Nursing, Universidade Federal de Sergipe, Lagarto, Brasil
- 7Global Health and Tropical Medicine (GHTM), Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisbon, Portugal
- 8College of Pharmaceutical Sciences, Federal University of Vale do São Francisco (UNIVASF), Petrolina, Brazil
- 9Department of Medicine, Universidade Federal de Alagoas, Arapiraca, Brazil
- 10Department of Morphology, Universidade Federal de Sergipe, São Cristóvão, Brazil
- 11Laboratory of Immunology and Molecular Biology, University Hospital, Universidade Federal de Sergipe, Aracaju, Brazil
A Corrigendum on
Impact of the COVID-19 pandemic on the diagnosis of tuberculosis in Brazil: Is the WHO end TB strategy at risk?
by Souza MdR, Paz WSd, Sales VBdS, Jesus GFHd, Tavares DdS, Lima SVMA, Sousa ÁFL, Melo EVd, Carmo RFd, Souza CDFd and Bezerra-Santos M (2022) Front. Pharmacol. 13:891711. doi: 10.3389/fphar.2022.891711
In the published article, there was an error in the Funding statement. The manuscript was published without due mention of the funding agency. The correct Funding statement appears below.
“Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade NOVA de Lisboa, Portugal, ref. UID/04413/2020.”
In addition, the article was published without including the acknowledgments. The correct Acknowledgments statement appears below.
“Foundation for Science and Technology (Fundação para a Ciência e tecnologia) for funds to GHTM – UID/04413/2020”
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: tuberculosis, COVID-19, COVID-19 pandemic, end TB strategy, global health
Citation: Rosário Souza Md, Silva da Paz W, dos Santos Sales VB, Hilario de Jesus GF, dos Santos Tavares D, Almeida Lima SVM, Lopes Sousa ÁF, Vieira de Melo E, Feliciano do Carmo R, Freire de Souza CD and Bezerra-Santos M (2022) Corrigendum: Impact of the COVID-19 pandemic on the diagnosis of tuberculosis in Brazil: Is the WHO end TB strategy at risk?. Front. Pharmacol. 13:999301. doi: 10.3389/fphar.2022.999301
Received: 20 July 2022; Accepted: 25 July 2022;
Published: 06 September 2022.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2022 Rosário Souza, Silva da Paz, dos Santos Sales, Hilario de Jesus, dos Santos Tavares, Almeida Lima, Lopes Sousa, Vieira de Melo, Feliciano do Carmo, Freire de Souza and Bezerra-Santos. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Álvaro Francisco Lopes Sousa, c291c2EuYWx2YXJvbWRAZ21haWwuY29t